Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Deep Dives
Consulting
Archive
About
Latest
Top
Discussions
CEPI Rescues Moderna’s Bird Flu Vaccine and Takeda’s Delivers in Psoriasis — This Week in Biotech #82
From pandemic preparedness to late stage clinical wins, plus key FDA approvals and trial readouts that will shape 2026 (Dec 12-18, 2025).
Dec 19
•
Katerina Roznik
1
1
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
Plus Biohaven’s next-gen Trop2 data, Kymera’s STAT6 surge, AC Immune’s Parkinson’s signal, Mirum’s hepatitis delta bet, the CDC’s new Covid vaccine…
Dec 12
•
Katerina Roznik
1
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
Founder Josep Bassaganya-Riera on omilancor, a gut-restricted oral therapy, precision biomarkers in inflammatory bowel disease, and the TITAN-X AI…
Dec 10
•
Katerina Roznik
5
1
1
FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80
Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec…
Dec 5
•
Katerina Roznik
7
2
3
November 2025
CDC’s Autism Reversal Shocks Experts, mRNA Flu Shot Advances, Big Oncology Wins — This Week in Biotech #79
Plus Arrowhead’s first approval, Abbott buys Exact Sciences, Merck bets $9.2B on flu prevention, and fresh takeover buzz in gene editing and IBD (Nov…
Nov 21
•
Katerina Roznik
9
2
FDA Opens New Pathway and Biotech’s Return to Offense — This Week in Biotech #78
A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins (Nov 7-13, 2025).
Nov 14
•
Katerina Roznik
4
2
1
Inside Sensible Biotechnologies: Reinventing mRNA Manufacturing
How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
Nov 13
•
Katerina Roznik
4
2
2
Trump Reshapes Obesity Drug Prices, Novo Tops Pfizer Again — This Week in Biotech #77
Politics, pricing, and pipelines collide. From GLP-1 wars and TrumpRx to Moderna’s refocus and J&J’s Caplyta win (Oct 31-Nov 6, 2025).
Nov 7
•
Katerina Roznik
4
2
2
October 2025
Novo tops Pfizer’s obesity bid; FDA moves to speed biosimilar approvals; Moderna–Merck rumors build — This Week in Biotech #76
Plus Novartis bets $12B on RNA delivery; Intensity’s tumor injection therapy stuns with 400% stock surge, and BridgeBio cements rare-disease momentum…
Oct 31
•
Katerina Roznik
6
1
Drug launch prices soar; mRNA shots linked to longer cancer survival — This Week in Biotech #75
ICER flags +51% net launch prices, Novo board shake-up, Tecentriq’s ctDNA-guided bladder success, Exelixis OS bump in colorectal cancer, and Ideaya…
Oct 24
•
Katerina Roznik
5
3
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Moderna and BioNTech deploy AI-driven mRNA to target CMV, EBV, HSV, and personalized neoantigen cancer vaccines. These trials could redefine…
Oct 21
•
Katerina Roznik
and
The Biotech Capital Compass
8
5
3
Trump cuts IVF & Medicaid drug prices; Novo buys Omeros; Lilly's GLP-1 orforglipron shines — This Week in Biotech #74
Plus: BioCryst-Astria rounds out HAE, Praxis’ essential tremor pill succeeds in Phase 3, and Rocket’s LAD-I gene therapy returns to FDA review (Oct…
Oct 17
•
Katerina Roznik
5
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
